PRODUCT DESCRIPTION:

Rocuronium Bromide Injection is a non-depolarizing neuromuscular blocking agent used to facilitate rapid sequence intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.

It acts by competitively inhibiting acetylcholine at the neuromuscular junction, leading to reversible muscle paralysis.

With its rapid onset and intermediate duration of action, Rocuronium is often preferred in emergency and operative settings where quick and controlled intubation is required.

It offers a reliable profile for use in both adult and pediatric patients, especially in high-dependency areas such as ICUs, operation theatres, and critical care units.

Formulation & Presentation:

• Dosage Form: Sterile Injectable
• Presentation: Clear Sterile Solution in Clear/Amber Glass Vial/ Ampoule (customizable as per market demand)
• Available Strengths:
  • Rocuronium Bromide Injection: 10MG/ ML
• Route of Administration: Via Intravenous Bolus (IV) or Continuous Infusion only or as advised by physician. To be used after appropriate reconstitution or as per clinical indication and recommendation. Reconstituted as per protocol for injection in country of use. To be administered under strict supervision of a qualified doctor or as per physician’s discretion or decision only.

Therapeutic Indications:

• Immediate reversal of unfractionated heparin anticoagulation
• Management of heparin overdose in surgical and non-surgical settings
• Heparin neutralization after cardiopulmonary bypass, extracorporeal circulation, or hemodialysis

Side Effects:

• COMMON:
  • Injection site pain
  • Transient hypotension
  • Increased salivation
  • Tachycardia
• SERIOUS (RARE):
  • Anaphylactic reactions
  • Prolonged neuromuscular blockade
  • Bronchospasm
  • Arrhythmias
• PRECAUTIONS:
  • Only for use by trained healthcare professionals in a controlled environment
  • Continuous respiratory monitoring and ventilatory support must be available
  • Use with caution in patients with neuromuscular diseases, hepatic impairment, or electrolyte imbalances
  • Dosage adjustment may be needed in elderly or obese patients
  • Reversal agents (e.g., sugammadex, neostigmine) should be readily available